Aflibercept T&E regimens appear effective in polypoidal choroidal vasculopathy subgroup

Individualized treat-and-extend (T&E) regimens with intravitreal aflibercept (IVT-AFL) in a subgroup of treatment-naïve exudative age-related macular degeneration (AMD) patients with polypoidal choroidal vasculopathy (PCV) improved and maintained functional and anatomic outcomes over 96 weeks, according to a study.

In this randomized, open-label, phase 4 study, 90 patients received 3 initial monthly doses and IVT-AFL at week 16. Patients were then randomized to receive either 2-week (IVT-AFL-2W) or 4-week (IVT-AFL-4W) adjustments.

From baseline to week 52 in the IVT-AFL-2W group, mean (SD) change in best-corrected visual acuity (BCVA) was + 7.5 (14.7) letters and mean (SD) change in central retinal thickness was – 153 (177) µm. From baseline to week 96, 91.3% of patients in this group maintained vision.

From baseline to week 52 in the IVT-AFL-4W group, mean (SD) change in BCVA was+ 8.2 (11.6) letters and mean (SD) change in central retinal thickness was and -112 (122) µm. From baseline to week 96, 90.9% of patients in this group maintained vision.

A treatment interval of 16 weeks between weeks 16 and 96 was achieved in 43.5% of patients in the IVT-AFL-2W group and 59.1% of patients in the IVT-AFL-4W group.

Reference
Okada AA, Takahashi K, Ohji M; ALTAIR Study Investigators. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Adv Ther. 2022;doi: 10.1007/s12325-022-02162-w. Epub ahead of print. PMID: 35503499.